Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CHECKVacc

Next Previous
Drug Profile

CHECKVacc

Alternative Names: CF 33 engineered with anti PD-L1 - City of Hope/Imugene; CF-33 & aPD-L1 - City of Hope/Imugene; CF33-hNIS-antiPDL1; Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody

Latest Information Update: 28 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Imugene
  • Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Immunologic cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Triple negative breast cancer

Most Recent Events

  • 28 Nov 2024 No recent reports of development identified for phase-I development in Triple-negative-breast-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Intratumoural, Injection)
  • 05 Nov 2024 Imugene receives patent extension in USA
  • 19 Jan 2024 Efficacy data from a phase I trial in Triple negative breast cancer released by Imugene

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top